# US 2004/0001847 A1 · Method and composition to elicit an effective autologous antitumoral immune response in a patient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0001847 A1
- Document ID: US20040001847A1
- Status: Published application
- Kind: A1
- Application number: 10/607,358
- Filed: 2003-06-26
- Published: 2004-01-01
- Earliest claimed: 2002-06-26
- Inventors: Eduardo M. Lasalvia-Prisco
- Web page: https://patentgrep.com/patent/US20040001847A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method and a composition to elicit an effective antitumoral immune response in a patient, specific to his or her own tumor antigens (i.e. an autologous antitumoral immune response), wherein the method preferably elicits an effective autologous antitumoral immune response in a cancer patient. The method includes generating, preserving, and storing specific tumor associated antigens or TAA, and eliciting the autologous antitumoral immune response, at least in part, through a combination of dual vaccines. Specifically, the method provides for both an internal and external vaccine. Additionally, the preparation of an autologous hemoderivative composition for utilization as the an external vaccine is presented, as well as the autologous hemoderivative composition itself.

## Claims

### Claim 1

A method to elicit an effective antitumoral immune response in a patient comprising:
generating a plurality of tumor associated antigens (TAA) in a plurality of cells in the patient,
inhibiting an immune tolerance response relative to the TAA in the patient to enhance the antitumoral immune response,
activating a plurality of antigen presenting cells (APC) in the patient to further enhance the antitumoral immune response,
triggering an internal vaccine in the patient to at least partially elicit the antitumoral immune response, and
providing an external vaccine to the patient to further elicit the antitumoral immune response.

### Claim 2 (depends on 1)

A method as recited in claim 1 further comprising generating the TAA in a plurality of tumor cells of the patient.

### Claim 3 (depends on 1)

A method as recited in claim 1 further comprising preserving the TAA in the patient.

### Claim 4 (depends on 3)

A method as recited in claim 3 wherein preserving the TAA further comprises inducing the synthesis of a plurality of stress shock proteins (SSP).

### Claim 5 (depends on 4)

A method as recited in claim 4 wherein inducing the synthesis of the SSP comprises administering indomethacin to the patient.

### Claim 6 (depends on 4)

A method as recited in claim 4 wherein inducing the synthesis of the SSP comprises administering a corticoid compound to the patient.

### Claim 7 (depends on 1)

A method as recited in claim 1 further comprising storing the TAA in the plurality of cells of the patient.

### Claim 8 (depends on 7)

A method as recited in claim 7 wherein storing the TAA further comprises inducing the synthesis of a plurality of stress shock proteins (SSP).

### Claim 9 (depends on 8)

A method as recited in claim 8 wherein inducing the synthesis of the SSP comprises administering indomethacin to the patient.

### Claim 10 (depends on 8)

A method as recited in claim 8 wherein inducing the synthesis of the SSP comprises administering a corticoid compound to the patient.

### Claim 11 (depends on 1)

A method as recited in claim 1 wherein generating the TAA further comprises inducing protein synthesis in the plurality of cells of the patient.

### Claim 12 (depends on 1)

A method as recited in claim 1 further comprising inducing protein synthesis in the plurality of cells of the patient via administering a pharmaceutical compound to the patient.

### Claim 13 (depends on 12)

A method as recited in claim 12 further comprising administering a pharmaceutical compound to the patient comprising insulin.

### Claim 14 (depends on 1)

A method as recited in claim 1 wherein generating the TAA further comprises administering insulin to the patient.

### Claim 15 (depends on 1)

A method as recited in claim 1 wherein generating the TAA comprises administering at least one DNA targeted chemotherapeutical to the patient.

### Claim 16 (depends on 15)

A method as recited in claim 15 further comprising administering at least one DNA targeted chemotherapeutical comprising cyclophosphamide to the patient.

### Claim 17 (depends on 15)

A method as recited in claim 15 further comprising administering at least one DNA targeted chemotherapeutical comprising methotrexate to the patient.

### Claim 18 (depends on 15)

A method as recited in claim 15 further comprising administering at least one DNA targeted chemotherapeutical comprising fluorouracil to the patient.

### Claim 19 (depends on 1)

A method as recited in claim 1 wherein activating the APC in the patient comprises administering a cytokine to the patient.

### Claim 20 (depends on 19)

A method as recited in claim 19 further comprising administering the cytokine comprising granulocyte-macrophage colony stimulating factor (GM-CSF) to the patient.

### Claim 21 (depends on 1)

A method as recited in claim 1 wherein inhibiting the immune tolerance response for the TAA comprises administering cyclophosphamide to the patient.

### Claim 22 (depends on 1)

A method as recited in claim 1 wherein triggering the internal vaccine in the patient comprises inducing cell death in the plurality of cells in the patient.

### Claim 23 (depends on 22)

A method as recited in claim 22 further comprising inducing immunogenic cell death in a plurality of tumor cells in the patient.

### Claim 24 (depends on 22)

A method as recited in claim 22 further comprising inducing immunogenic cell death in the plurality of cells in the patient via apoptosis.

### Claim 25 (depends on 24)

A method as recited in claim 24 further comprising exposing the plurality of cells to cellular stress prior to inducing immunogenic cell death in the plurality of cells in the patient via apoptosis.

### Claim 26 (depends on 22)

A method as recited in claim 22 further comprising inducing immunogenic cell death in the plurality of cells in the patient via autoschizis.

### Claim 27 (depends on 26)

A method as recited in claim 26 wherein inducing immunogenic cell death in the plurality of cells in the patient via autoschizis comprises administering ascorbic acid to the patient.

### Claim 28 (depends on 27)

A method as recited in claim 27 further comprising administering the ascorbic acid to the patient intravenously.

### Claim 29 (depends on 27)

A method as recited in claim 27 wherein inducing immunogenic cell death in the plurality of cells in the patient via autoschizis further comprises simultaneously administering menadione to the patient.

### Claim 30 (depends on 29)

A method as recited in claim 29 further comprising administering menadione to the patient intravenously.

### Claim 31 (depends on 1)

A method as recited in claim 1 wherein providing the external vaccine to the patient further comprises inoculating the patient with the external vaccine subcutaneously.

### Claim 32 (depends on 1)

A method as recited in claim 1 wherein providing the external vaccine to the patient further comprises inoculating the patient with the external vaccine via intradermal inoculation.

### Claim 33 (depends on 1)

A method as recited in claim 1 wherein providing the external vaccine to the patient further comprises inoculating the patient with the external vaccine via intramuscular inoculation.

### Claim 34

A method to elicit an effective antitumoral immune response in a patient comprising:
completing at least one treatment cycle, each treatment cycle comprising,
administering insulin to the patient during a preparatory treatment phase,
administering at least one DNA targeted chemotherapeutical to the patient during the preparatory treatment phase,
administering cyclophosphamide to the patient during a first intermediate treatment phase,
administering a cytokine to the patient during a primary treatment phase,
administering ascorbic acid to the patient during the primary treatment phase,
administering menadione to the patient during the primary treatment phase, and
administering a hemoderivative composition to the patient during a secondary treatment phase.

### Claim 35 (depends on 34)

A method as recited in claim 34 further comprising administering the insulin to the patient on each of days one through four of the treatment cycle.

### Claim 36 (depends on 34)

A method as recited in claim 34 further comprising administering the insulin to the patient on each of days one through five of the treatment cycle.

### Claim 37 (depends on 34)

A method as recited in claim 34 further comprising administering the insulin to the patient each day of the preparatory treatment phase at a daily dosage of approximately 0.3 international units per kilogram of the patient's body weight.

### Claim 38 (depends on 34)

A method as recited in claim 34 further comprising administering the at least one DNA targeted chemotherapeutical to the patient on each of days one through four of the treatment cycle.

### Claim 39 (depends on 34)

A method as recited in claim 34 further comprising administering the at least one DNA targeted chemotherapeutical to the patient on each of days one through five of the treatment cycle.

### Claim 40 (depends on 34)

A method as recited in claim 34 further comprising administering the at least one DNA targeted chemotherapeutical comprising cyclophosphamide to the patient each day of the preparatory treatment phase at a daily dosage in a range of between approximately 100 to 200 milligrams.

### Claim 41 (depends on 34)

A method as recited in claim 34 further comprising administering the at least one DNA targeted chemotherapeutical comprising methotrexate to the patient each day of the preparatory treatment phase at a daily dosage in a range of between approximately 2.5 to 12.5 milligrams.

### Claim 42 (depends on 34)

A method as recited in claim 34 further comprising administering the at least one DNA targeted chemotherapeutical comprising fluorouracil to the patient each day of the preparatory treatment phase at a daily dosage in a range of between approximately 125 to 250 milligrams.

### Claim 43 (depends on 34)

A method as recited in claim 34 further comprising administering the cyclophosphamide to the patient on day five of the treatment cycle.

### Claim 44 (depends on 34)

A method as recited in claim 34 further comprising administering the cyclophosphamide to the patient each day of the first intermediate treatment phase at a daily dosage of approximately 300 milligrams per square meter of surface area of the patient's body.

### Claim 45 (depends on 34)

A method as recited in claim 34 further comprising administering the cytokine to the patient on each of days eight through twelve of the treatment cycle.

### Claim 46 (depends on 34)

A method as recited in claim 34 further comprising administering the cytokine comprising granulocyte-macrophage colony stimulating factor (GM-CSF) to the patient on each day of the primary treatment phase at a daily dosage in a range of between approximately 150 to 250 micrograms.

### Claim 47 (depends on 34)

A method as recited in claim 34 further comprising administering the ascorbic acid to the patient on each of days eight through twelve of the treatment cycle.

### Claim 48 (depends on 34)

A method as recited in claim 34 further comprising administering the ascorbic acid to the patient each day of the primary treatment phase at a daily dosage of approximately 25 grams in a solution of approximately 250 milliliters of a lactate-ringer solution.

### Claim 49 (depends on 48)

A method as recited in claim 48 further comprising administering the ascorbic acid to the patient intravenously.

### Claim 50 (depends on 34)

A method as recited in claim 34 further comprising administering the menadione to the patient on each of days eight through twelve of the treatment cycle.

### Claim 51 (depends on 34)

A method as recited in claim 34 further comprising administering the menadione to the patient each of day the primary treatment phase at a daily dosage of approximately 250 milligrams.

### Claim 52 (depends on 51)

A method as recited in claim 51 further comprising administering the menadione to the patient intravenously.

### Claim 53 (depends on 51)

A method as recited in claim 51 further comprising administering menadione to the patient orally.

### Claim 54 (depends on 34)

A method as recited in claim 34 further comprising administering the hemoderivative composition to the patient on each day of the secondary treatment phase.

### Claim 55 (depends on 34)

A method as recited in claim 34 further comprising administering an autologous hemoderivative composition to the patient on each day of the secondary treatment phase.

### Claim 56 (depends on 34)

A method as recited in claim 34 further comprising administering the hemoderivative composition to the patient on each of days fifteen, seventeen, nineteen, twenty-two, twenty-four, and twenty-six of the treatment cycle.

### Claim 57 (depends on 34)

A method as recited in claim 34 further comprising administering cyclophosphamide to the patient each day of a second intermediate treatment phase at a daily dosage of approximately 300 milligrams per square meter of surface area of the patient's body.

### Claim 58 (depends on 57)

A method as recited in claim 57 further comprising administering the cyclophosphamide to the patient on day thirteen of the treatment cycle.

### Claim 59 (depends on 34)

A method as recited in claim 34 further comprising completing a plurality of treatment cycles.

### Claim 60

A method of preparation of an autologous hemoderivative composition for use in eliciting an effective antitumoral immune response in a patient comprising:
extracting a blood specimen from the patient and forming a blood specimen solution,
separating a supernatant plasma-cell layer from the blood specimen solution after settling,
diluting the supernatant plasma-cell layer in a dilutant forming a plasma-cell solution and thereby inducing a hypotonic shock,
cooling and heating the plasma-cell solution and thereby inducing a hypothermic shock,
fractioning the plasma-cell solution by heating to a predetermined temperature for a predetermined period of time and forming a plasma-cell fraction, and filtering the plasma-cell fraction prior to administrating to the patient.

### Claim 61 (depends on 60)

A method of preparation as recited in claim 60 further comprising extracting approximately 20 milliliters of the blood specimen from the femoral artery of the patient into a heparin solution thereby forming the blood specimen solution.

### Claim 62 (depends on 60)

A method of preparation as recited in claim 60 further comprising settling the blood specimen solution for approximately one hour and separating the supernatant plasma-cell layer.

### Claim 63 (depends on 60)

A method of preparation as recited in claim 60 further comprising diluting the supernatant plasma-cell layer in distilled water at a ratio in a range of approximately 3 to 4 parts distilled water per 1 part supernatant plasma-cell layer, thereby forming the plasma-cell solution.

### Claim 64 (depends on 60)

A method of preparation as recited in claim 60 further comprising cooling the plasma-cell solution to approximately minus twenty degrees centigrade for approximately 24 hours.

### Claim 65 (depends on 60)

A method of preparation as recited in claim 60 further comprising fractioning the plasma-cell solution by heating to approximately one hundred degrees centigrade for between approximately 8 to 10 minutes.

### Claim 66

An autologous hemoderivative composition comprising:
a plasma-cell solution cooled to approximately minus twenty degrees centigrade for approximately 24 hours, and subsequently heated to approximately 100 degrees centigrade for between approximately 8 to 10 minutes, and filtered after cooling,
said plasma-cell solution being defined by a supernatant plasma-cell layer separated from a blood specimen solution and a quantity of distilled water, and
said blood specimen solution comprising a blood specimen extracted from a femoral artery of a patient and a heparin solution.
